Bioengineering to combat the tuberculosis pandemic

Project overview

We will combine engineering and biological approaches to investigate the host-pathogen interaction and identify new therapeutic targets.

Staff

Lead researcher

Professor Paul Elkington

Director of Inst. for Medical Innovation

Research interests

tuberculosis
immunopathology
diagnosis

Connect with Paul

Email: P.Elkington@soton.ac.uk

Other researchers

Professor Xunli Zhang PhD, DIC, FRSC, CChem, CEng

Head of Department-Chemical Engineerg

Research interests

Xunli’s key expertise lies in the area of microfluidics technology from design and fabrication of microfluidic devices, through the development of in-situ monitoring methods for bio/chemical processes, to microfluidic modelling, microsystems integration and automation. The application is largely associated with biomedical challenges like patient specific design of microfluidic devices for cancer treatment, rapid diagnosis, and tackling antimicrobial resistance (AMR). The continuous flow reactors have been used for the synthesis of a range of nanoparticles, both organic and inorganic, for application in drug delivery and energy saving. The technologies developed in his research have also found great potential for industrial applications through a variety of industrial collaborations.

Connect with Xunli

Email: XL.Zhang@soton.ac.uk

Research outputs

Personal respirators for population level control of the COVID19 pandemic

Paul Elkington & Hywel Morgan, 2020, Journal of Infection, 81(2), 318-356

DOI: 10.1016/j.jinf.2020.04.025

Type: letterEditorial

Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-alpha

Liku Bekele Tezera, Magdalena Bielecka, Paul Ogongo, Naomi Walker, Matthew Ellis, Diana J. Garay-Baquero, Kristian Thomas, MICHAELA REICHMANN, David Johnston, Katalin Wilkinson, Mohamed Ahmed, Sanjay Jogai, Suwan N. Jayasinghe, Robert J. Wilkinson, Salah Mansour, Gareth Thomas, Christian Ottensmeier, Alasdair Leslie & Paul Elkington, 2020, eLife, 9

DOI: 10.7554/eLife.52668

Type: article

Reconsidering the optimal immune response to Mycobacterium tuberculosis

Liku Bekele Tezera, Salah Mansour & Paul Elkington, 2019, American Journal of Respiratory and Critical Care Medicine, 201(4)

DOI: 10.1164/rccm.201908-1506PP

Type: review

In vitro granuloma models of tuberculosis

Paul Elkington, Maria Lerm, Nidhi Kapoor, Robert Mahon, Elsje Pienaar, Dongeun Huh, Deepak Kaushal & Larry Schlesinger, 2019, Journal of Infectious Diseases, 219(12), 1858–1866

DOI: 10.1093/infdis/jiz020

Type: review

Implications of tuberculosis reactivation after immune checkpoint inhibition

Paul Elkington, Adrian Bateman, Gareth Thomas & Christian Ottensmeier, 2018, American Journal of Respiratory and Critical Care Medicine, 198(11), 1451-1453

DOI: 10.1164/rccm.201807-1250LE

Type: letterEditorial